

References

I-172

1. Cherukuri A, Cahan H, Tuyl AV, et al. Immunogenicity to cerliponase alfa, an enzyme replacement therapy for patients with CLN2 disease: results from a phase 1/2 study. *Molecular Genetics and Metabolism*. 2017;S35.
2. Schulz A, Specchio N, Gissen P, et al. Long-term safety and efficacy of intracerebroventricular enzyme replacement therapy with cerliponase alfa in children with CLN2 disease: interim results from an ongoing multicenter, multinational extension study. *Molecular Genetics and Metabolism*. 2017;S120.
3. Fietz M, AlSayed M, Burke D, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. *Molecular Genetics and Metabolism*. 2016;160-167.
4. MICROMEDEX DrugDex Compendium®. 2021. Cerliponase Alfa (Brineura).
5. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Cerliponase alfa.
6. Brineura (cerliponase alfa) injection, for intraventricular use [package insert]. BioMarin Pharmaceutical Inc. Novato, CA Revised 03/2020.
7. Hayes, Inc. Hayes Prognosis Overview. Brineura (Cerliponase alfa). Landsdale, PA: Hayes, Inc.; July 2018.
8. Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. *New England Journal of Medicine*. 2018;378:1898-1907.
9. U.S. Department of Health and Human Services, National Institute of Health, The National Institute of Neurological Disorders and Stroke. Batten Disease. Date modified: July 2018.
10. de los Reyes E, Lehwald L, Ausutine E, et al. Intracerebroventricular cerliponase alfa for CLN2 disease: Clinical practice considerations from US clinic. *Pediatric Neurology*. 2020.
11. Carvalho J. Brineura shows promise delaying disease progression in children with CLN2, review suggests. *Batten Disease News*. Published April 24, 2020. Accessed June 23, 2020.
12. Kim A, Grover A, Hammon K, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration. *CTS: Clinical & Translational Science*. 2021;14(2):635-644.

13. Wibbeler E, Wang R, Reyes EL, et. al. Cerliponase alfa for the treatment of atypical phenotypes of CLN2 Disease: A retrospective case series. *J Child Neurol.* 2021;36(6):468-474.